1878-A INDIVIDUALIZED HCV TREATMENT FOR PWIDS ON OPIOID AGONIST THERAPY LED TO EXCELLENT ADHERENCE THROUGHOUT THE COVID19 PANDEMIC Caroline Schwarz 1,2 , Angelika Schtz 3 , Raphael Schubert 3 , Michael Schwarz 2 , Anika Jenke 3 , David Josef Maria Bauer 1,2 , Lukas Burghart 1,2 , Benjamin Steinwender 3 , Enisa Gutic 1 , Thomas Reiberger 2,4 , Hans Haltmayer 3 and Michael Gschwantler 1,5 , (1)Klinik Ottakring, (2)Medical University of Vienna, (3)Suchthilfe Wien Ggmbh, (4)Cemm Research Center for Molecular Medicine of the Austrian Academy of Sciences, (5)Sigmund Freud University Background: Directly observed therapy (DOT) with DAAs (direct-acting antivirals) is successful in eliminating HCV in PWIDs (people who inject drugs) on opioid agonist therapy (OAT): DAAs are prescribed via a low-threshold facility (LTF), and supervised DAA administration alongside OAT is performed at a pharmacy or LTF
Premiere preuve d'immunoregulation VIP chez l'humain
The natural yellow tint is proof of its uncompromised purity
Vitamin B12 Deficiency: This vitamin is essential for nerve health
doi: 10.1164/rccm.200612-1804OC 109 UsherLRLawsonRAGearyITaylorCJBingleCDTaylorGWet al
